Actavis Fails to Knock Out First Testosterone Replacement Trial

A man who had allegedly had a heart attack after taking Actavis Inc.'s Androderm testosterone-replacement therapy may proceed to trial, and punitive damages remain on the table, a federal court in Illinois ruled.

And medical experts for plaintiff Brad Martin and his wife may testify in what would be the first bellwether trial in the consolidated litigation over Actavis’s TRT products, the U.S. District Court for the Northern District of Illinois said.

Martin alleges Actavis improperly marketed Androderm for an age-related reduction in testosterone, rather than the endocrine disorder, “classical” hypogonadism, for which the Food and Drug Administration approved it. ...